Tetrahydrocannabivarin
A unique cannabinoid that suppresses appetite and may benefit metabolic health
Tetrahydrocannabivarin (THCV) is a propyl analog of THC with a distinct and in some ways opposite pharmacological profile. At low doses it acts as a CB1 antagonist (suppressing appetite and reducing THC's psychoactive effects); at high doses it becomes a CB1 agonist. THCV has significant potential for metabolic disorders, diabetes, and appetite regulation.
Primary Receptors & Targets
THCV's most distinctive pharmacological feature is its dose-dependent CB1 activity. At low doses (below approximately 5mg in humans), THCV acts as a CB1 neutral antagonist — blocking THC and endocannabinoids from activating CB1 receptors. This produces appetite suppression (the opposite of THC's munchies effect) and may reduce THC's psychoactive effects when both are present.
At higher doses, THCV becomes a CB1 agonist, producing psychoactive effects similar to THC but with a faster onset and shorter duration (approximately 2 hours vs. 4–6 hours for THC).
THCV's metabolic effects involve both CB1 antagonism (which improves insulin sensitivity and reduces food intake) and CB2 agonism (which modulates adipose tissue inflammation). The combination may explain its observed benefits in type 2 diabetes models.
2013 GW Pharmaceuticals study: THCV improved fasting plasma glucose and adiponectin levels in type 2 diabetic patients.
CB1 antagonism at low doses suppresses appetite; animal studies show reduced food intake and improved insulin sensitivity.
THCV demonstrated anticonvulsant properties in multiple animal seizure models.
THCV reduced motor deficits and protected dopaminergic neurons in a mouse model of Parkinson's disease.
THCV stimulated bone nodule formation and collagen production via CB2 receptors in vitro.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
Diabetes Care
THCV significantly improved fasting plasma glucose, adiponectin, and apolipoprotein A in type 2 diabetic patients in a randomized controlled trial.
British Journal of Pharmacology
THCV reduced motor deficits and protected dopaminergic neurons in a 6-OHDA mouse model of Parkinson's disease.
Epilepsia
THCV demonstrated anticonvulsant effects in multiple seizure models, including models relevant to absence epilepsy.
The global epidemic of metabolic syndrome — characterized by obesity, insulin resistance, dyslipidemia, and hypertension — represents one of the most significant unmet medical needs of our time. THCV's combination of CB1 antagonism (improving insulin sensitivity and suppressing appetite) and CB2 agonism (reducing adipose inflammation) positions it as a potentially valuable tool in metabolic disease management. GW Pharmaceuticals conducted a Phase 2a trial of THCV in type 2 diabetes that produced encouraging results, and several companies are pursuing THCV-based pharmaceutical development. The challenge is that THCV is present in very low concentrations in most cannabis cultivars, making standardized production expensive.